A potent and selective inhibitor for the UBLCP1 proteasome phosphatase

Yantao He, Xing Guo, Zhi Hong Yu, Li Wu, Andrea M. Gunawan, Yan Zhang, Jack E. Dixon, Zhong-Yin Zhang

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The ubiquitin-like domain-containing C-terminal domain phosphatase 1 (UBLCP1) has been implicated as a negative regulator of the proteasome, a key mediator in the ubiquitin-dependent protein degradation. Small molecule inhibitors that block UBLCP1 activity would be valuable as research tools and potential therapeutics for human diseases caused by the cellular accumulation of misfold/damaged proteins. We report a salicylic acid fragment-based library approach aimed at targeting both the phosphatase active site and its adjacent binding pocket for enhanced affinity and selectivity. Screening of the focused libraries led to the identification of the first potent and selective UBLCP1 inhibitor 13. Compound 13 exhibits an IC<inf>50</inf> of 1.0 μM for UBLCP1 and greater than 5-fold selectivity against a large panel of protein phosphatases from several distinct families. Importantly, the inhibitor possesses efficacious cellular activity and is capable of inhibiting UBLCP1 function in cells, which in turn up-regulates nuclear proteasome activity. These studies set the groundwork for further developing compound 13 into chemical probes or potential therapeutic agents targeting the UBLCP1 phosphatase.

Original languageEnglish
Pages (from-to)2798-2809
Number of pages12
JournalBioorganic and Medicinal Chemistry
Volume23
Issue number12
DOIs
StatePublished - Jan 22 2015

Fingerprint

Proteasome Endopeptidase Complex
Ubiquitin
Phosphoric Monoester Hydrolases
Libraries
Salicylic Acid
Phosphoprotein Phosphatases
Corrosion inhibitors
Proteolysis
Inhibitory Concentration 50
Catalytic Domain
Screening
Proteins
Up-Regulation
Degradation
Molecules
Therapeutics
Research

Keywords

  • Fragment-based drug discovery
  • Inhibitor development
  • Protein phosphatase
  • UBLCP1

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Molecular Biology
  • Molecular Medicine
  • Organic Chemistry
  • Drug Discovery
  • Pharmaceutical Science

Cite this

A potent and selective inhibitor for the UBLCP1 proteasome phosphatase. / He, Yantao; Guo, Xing; Yu, Zhi Hong; Wu, Li; Gunawan, Andrea M.; Zhang, Yan; Dixon, Jack E.; Zhang, Zhong-Yin.

In: Bioorganic and Medicinal Chemistry, Vol. 23, No. 12, 22.01.2015, p. 2798-2809.

Research output: Contribution to journalArticle

He, Y, Guo, X, Yu, ZH, Wu, L, Gunawan, AM, Zhang, Y, Dixon, JE & Zhang, Z-Y 2015, 'A potent and selective inhibitor for the UBLCP1 proteasome phosphatase', Bioorganic and Medicinal Chemistry, vol. 23, no. 12, pp. 2798-2809. https://doi.org/10.1016/j.bmc.2015.03.066
He, Yantao ; Guo, Xing ; Yu, Zhi Hong ; Wu, Li ; Gunawan, Andrea M. ; Zhang, Yan ; Dixon, Jack E. ; Zhang, Zhong-Yin. / A potent and selective inhibitor for the UBLCP1 proteasome phosphatase. In: Bioorganic and Medicinal Chemistry. 2015 ; Vol. 23, No. 12. pp. 2798-2809.
@article{eac966b43c0d4fc98428ee9187224b58,
title = "A potent and selective inhibitor for the UBLCP1 proteasome phosphatase",
abstract = "The ubiquitin-like domain-containing C-terminal domain phosphatase 1 (UBLCP1) has been implicated as a negative regulator of the proteasome, a key mediator in the ubiquitin-dependent protein degradation. Small molecule inhibitors that block UBLCP1 activity would be valuable as research tools and potential therapeutics for human diseases caused by the cellular accumulation of misfold/damaged proteins. We report a salicylic acid fragment-based library approach aimed at targeting both the phosphatase active site and its adjacent binding pocket for enhanced affinity and selectivity. Screening of the focused libraries led to the identification of the first potent and selective UBLCP1 inhibitor 13. Compound 13 exhibits an IC50 of 1.0 μM for UBLCP1 and greater than 5-fold selectivity against a large panel of protein phosphatases from several distinct families. Importantly, the inhibitor possesses efficacious cellular activity and is capable of inhibiting UBLCP1 function in cells, which in turn up-regulates nuclear proteasome activity. These studies set the groundwork for further developing compound 13 into chemical probes or potential therapeutic agents targeting the UBLCP1 phosphatase.",
keywords = "Fragment-based drug discovery, Inhibitor development, Protein phosphatase, UBLCP1",
author = "Yantao He and Xing Guo and Yu, {Zhi Hong} and Li Wu and Gunawan, {Andrea M.} and Yan Zhang and Dixon, {Jack E.} and Zhong-Yin Zhang",
year = "2015",
month = "1",
day = "22",
doi = "10.1016/j.bmc.2015.03.066",
language = "English",
volume = "23",
pages = "2798--2809",
journal = "Bioorganic and Medicinal Chemistry",
issn = "0968-0896",
publisher = "Elsevier Limited",
number = "12",

}

TY - JOUR

T1 - A potent and selective inhibitor for the UBLCP1 proteasome phosphatase

AU - He, Yantao

AU - Guo, Xing

AU - Yu, Zhi Hong

AU - Wu, Li

AU - Gunawan, Andrea M.

AU - Zhang, Yan

AU - Dixon, Jack E.

AU - Zhang, Zhong-Yin

PY - 2015/1/22

Y1 - 2015/1/22

N2 - The ubiquitin-like domain-containing C-terminal domain phosphatase 1 (UBLCP1) has been implicated as a negative regulator of the proteasome, a key mediator in the ubiquitin-dependent protein degradation. Small molecule inhibitors that block UBLCP1 activity would be valuable as research tools and potential therapeutics for human diseases caused by the cellular accumulation of misfold/damaged proteins. We report a salicylic acid fragment-based library approach aimed at targeting both the phosphatase active site and its adjacent binding pocket for enhanced affinity and selectivity. Screening of the focused libraries led to the identification of the first potent and selective UBLCP1 inhibitor 13. Compound 13 exhibits an IC50 of 1.0 μM for UBLCP1 and greater than 5-fold selectivity against a large panel of protein phosphatases from several distinct families. Importantly, the inhibitor possesses efficacious cellular activity and is capable of inhibiting UBLCP1 function in cells, which in turn up-regulates nuclear proteasome activity. These studies set the groundwork for further developing compound 13 into chemical probes or potential therapeutic agents targeting the UBLCP1 phosphatase.

AB - The ubiquitin-like domain-containing C-terminal domain phosphatase 1 (UBLCP1) has been implicated as a negative regulator of the proteasome, a key mediator in the ubiquitin-dependent protein degradation. Small molecule inhibitors that block UBLCP1 activity would be valuable as research tools and potential therapeutics for human diseases caused by the cellular accumulation of misfold/damaged proteins. We report a salicylic acid fragment-based library approach aimed at targeting both the phosphatase active site and its adjacent binding pocket for enhanced affinity and selectivity. Screening of the focused libraries led to the identification of the first potent and selective UBLCP1 inhibitor 13. Compound 13 exhibits an IC50 of 1.0 μM for UBLCP1 and greater than 5-fold selectivity against a large panel of protein phosphatases from several distinct families. Importantly, the inhibitor possesses efficacious cellular activity and is capable of inhibiting UBLCP1 function in cells, which in turn up-regulates nuclear proteasome activity. These studies set the groundwork for further developing compound 13 into chemical probes or potential therapeutic agents targeting the UBLCP1 phosphatase.

KW - Fragment-based drug discovery

KW - Inhibitor development

KW - Protein phosphatase

KW - UBLCP1

UR - http://www.scopus.com/inward/record.url?scp=84930085122&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930085122&partnerID=8YFLogxK

U2 - 10.1016/j.bmc.2015.03.066

DO - 10.1016/j.bmc.2015.03.066

M3 - Article

C2 - 25907364

AN - SCOPUS:84930085122

VL - 23

SP - 2798

EP - 2809

JO - Bioorganic and Medicinal Chemistry

JF - Bioorganic and Medicinal Chemistry

SN - 0968-0896

IS - 12

ER -